Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

NXG Cushing Midstream Energy Fund offers 16% yield driven by discount to NAV and rights offering structure.

Market News
08 Jun 2026
Seeking Alpha
View Source
Bullish
pluang ai news

The NXG Cushing Midstream Energy Fund (SRV) is notable for its high 16% distribution yield, but its returns are mainly influenced by its structure, including a November 2025 rights offering and trading at a discount to its net asset value (NAV). The fund invests in midstream energy assets benefiting from a natural gas tailwind, with holdings also trading below their long-term levels. Risks include leverage, a high return of capital in distributions, high expenses, and limited liquidity. The fund is rated Buy conditionally, depending on the premium/discount relationship to NAV, making it an attractive option for investors seeking income with some risk considerations.

More News

Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide

Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide

The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...

Market News
Neutral
2 hours ago
Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.

Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.

The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...

Market News
Bullish
3 hours ago
Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.

Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.

The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...

Market News
Bullish
3 hours ago
VINCI launches €200M share buyback program from June 11 to July 31, 2026

VINCI launches €200M share buyback program from June 11 to July 31, 2026

VINCI has initiated a share buyback program by signing an agreement with an investment services provider to repurchase its shares up to a limit of €200 million. The program runs from June 11 to July 31, 2026, with the purchase price capped by shareho...

Company Fundamentals
Bullish
3 hours ago
VINCI launches €200M share buyback program valid until July 31, 2026

VINCI launches €200M share buyback program valid until July 31, 2026

VINCI has initiated a share buyback program by signing an agreement with an investment service provider to repurchase its shares up to a value of €200 million. This program runs from June 11 to July 31, 2026, with purchase prices capped by the genera...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App